The main value of the COME HOME model for oncology practices is that it can help reduce hospitalization rates, leading to better quality of life for patients and clinicians, according to Barbara McAneny, MD, chief medical officer of New Mexico Oncology Hematology Consultants.
The main value of the COME HOME model for oncology practices is that it can help reduce hospitalization rates, leading to better quality of life for patients and clinicians, according to Barbara McAneny, MD, chief medical officer of New Mexico Oncology Hematology Consultants.
Transcript (slightly modified)
Are the oncology practices using COME HOME better equipped to fulfill requirements for the Quality Payment Program?
I believe that that is the main value of COME HOME. The processes that we’ve put in place with the triage pathways, where we give nurses the power of the schedule and a decision support tool to be able to make sure that they’re making the decisions that their physicians would want made, getting patients into the office for same-day visits, that’s what worked in COME HOME to cut down hospitalization rates.
Patients do better when they’re not in the hospital. Every time a patient goes into the hospital, they come out just a little less quality of life than they went in. They’re just not as strong or they got a bad infection or something else happened. So by keeping patients out of the hospital, we keep them healthier, which is the main goal, but we also save that money. That’s the low-hanging fruit.
The processes we created with COME HOME have allowed us to do multiple same-day visits and in my practice, we’ve cut our hospital admissions by over half, and that’s significant. It’s also significant not only for patient quality of life but for physician quality of life. If I don’t have so many people to round on in the hospital before I go to the office to do the day’s work, I can manage them much more easily.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More